Rafael Enríquez de Salamanca Lorente-rekin lankidetzan egindako argitalpenak (23)

2024

  1. Exploring current and emerging therapies for porphyrias

    Liver International, Vol. 44, Núm. 9, pp. 2174-2190

2023

  1. Diagnosis, evaluation and monitoring of acute hepatic porphyria

    Medicina Clinica

  2. Understanding Carbohydrate Metabolism and Insulin Resistance in Acute Intermittent Porphyria

    International Journal of Molecular Sciences, Vol. 24, Núm. 1

2021

  1. Acute intermittent porphyria, givosiran, and homocysteine

    Journal of Inherited Metabolic Disease

2020

  1. Porfirias

    Medicina interna [19ª ed.] (Elsevier España)

2018

  1. An Inducible Promoter Responsive to Different Porphyrinogenic Stimuli Improves Gene Therapy Vectors for Acute Intermittent Porphyria

    Human Gene Therapy, Vol. 29, Núm. 4, pp. 480-491

2015

  1. Vitamin D-binding protein as a biomarker of active disease in acute intermittent porphyria

    Journal of Proteomics, Vol. 127, pp. 377-385

2012

  1. Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates.

    Journal of translational medicine, Vol. 10, pp. 122

2009

  1. Epidermal growth factor receptor ligands in murine models for erythropoietic protoporphyria: Potential novel players in the progression of liver injury

    Cellular and Molecular Biology, Vol. 55, Núm. 1, pp. 29-37

  2. Identification and characterization of HMBS gene mutations in Spanish patients with acute intermittent porphyria

    Cellular and Molecular Biology, Vol. 55, Núm. 2, pp. 55-63

  3. Induction of hepatic aminolevulinate acid synthetase activity by isoflurane in a genetic model for erythropoietic protoporphyria

    Cellular and Molecular Biology, Vol. 55, Núm. 1, pp. 38-44

2008

  1. Bone marrow transplantation into hemochromatotic mice decreases hepatic and duodenal iron overload

    International Journal of Biochemistry and Cell Biology, Vol. 40, Núm. 1, pp. 135-146

2007

  1. Molecular heterogeneity of familial porphyria cutanea tarda in Spain: Characterization of 10 novel mutations in the UROD gene

    British Journal of Dermatology, Vol. 157, Núm. 3, pp. 501-507

2001

  1. Successful therapeutic effect in a mouse model of erythropoietic protoporphyria by partial genetic correction and fluorescence-based selection of hematopoietic cells

    Gene Therapy, Vol. 8, Núm. 8, pp. 618-626

2000

  1. Laboratory approximation to the diagnosis and typification of porphyria

    Anales de medicina interna (Madrid, Spain : 1984), Vol. 17, Núm. 11, pp. 609-613

1999

  1. Nonsynergic effect of ethanol and lead on heme metabolism in rats

    Ecotoxicology and Environmental Safety, Vol. 43, Núm. 1, pp. 98-102

1997

  1. Reduced aminolevulinate dehydrase activity in rats with functional renal failure induced by cyclosporin A

    Experimental Nephrology, Vol. 5, Núm. 4, pp. 323-329

  2. Reduced aminolevulinic dehydrase activity with increased blood porphyrins in experimental chronic renal failure

    Experimental Nephrology, Vol. 5, Núm. 1, pp. 95-99

1996

  1. Effects of recombinant human erythropoietin on porphyrin metabolism in uremic patients on hemodialysis

    Journal of the American Society of Nephrology, Vol. 7, Núm. 5, pp. 774-779

  2. Prevalencia de porfiria cutánea tarda en Madrid y asociación entre la porfirinuria y el consumo de etanol en un modelo de regresión lineal múltiple

    Medicina Clinica, Vol. 107, Núm. 16, pp. 614-616